DOCSLIB.ORG

Producto Precio ($) Producto Precio ($) Producto Precio ($)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Producto Precio ($) Producto Precio ($) Producto Precio ($) PRODUCTO PRECIO ($) PRODUCTO PRECIO ($) PRODUCTO PRECIO ($) PRODUCTO PRECIO ($) PRODUCTO PRECIO ($) PRODUCTO PRECIO ($) PRODUCTO PRECIO ($) ACEITE DE SALMON JGB ACETAMINOFEN LICOL ACIBIOGEL BIOGEN Fco. x 100 cáps. 46.797 Acetaminofén Hidrox de Alum, Mg-Sim Fco. x 50 cáps. 26.118 Ped. Jbe. Fco. x 60 mL 1.083 Fco. x 120 mL - Menta 3.835 ACEITE DE ZANAHORIA NATURAL FRESHLY 500 mg Caja x 100 tabs. 10.806 Fco. x 120 mL - Vainilla 3.835 A Fco. x 240 ml 11.900 ACETAMINOFEN LISTER Fco. x 360 mL - Guanabana 8.200 ACEITE FACIAL MEDICK Acetaminofén Fco. x 360 mL - Menta 8.200 ABACAVIR PROCLIN PHARMA x 10 mL 7.632+ Fco. x 30 capletas 3.778 Fco. x 360 mL - Vainilla 8.200 Fco. x 120 mL - Guanabana 3.835 20 mg/1mL Fco. x 240 mL Sol. oral 95.600 ACEITE HIGADO DE TIBURON MEDICK ACETAMINOFEN MEMPHIS 300 mg Fco. x 60 tabs. 168.200 x 60 perlas 16.319 Acetaminofén ACICLOVIR AMERICAN GENERICS ABACAVIR 600 mg+ Jbe. 150 mg/5 mL-Fco. x 60 mL 4.000 Aciclovir ACELLUVAX DPT BIOTOSCANA 200 mg x 30 tabs. 7.416 LAMIVUDINA 300 mg PROCLIN PHARMA Susp. estéril iny. 37.000 Jbe. 150 mg/5 mL-Fco. x 120 mL 5.000 500 mg-Caja x 100 tabs. 10.900 ACICLOVIR ANGLOPHARMA Fco. x 30 tabs. 185.000 ACEOTO PLUS ZAMBON Gotas-100 mg/1ml Fco. 15 mL 3.800 Aciclovir ABC KORPER FARMACARE x 10 mL 27.204 Fco. x 60 cáps. 32.000 Gotas-100 mg/1ml 1%-Fco. x 30 mL 4.000 Crema 5% Tubo x 15 g 2.620 ACETAMINOFEN AMERICA ABEFEN PISA FARMACEUTICA ACETAMINOFEN MK Polvo p/susp. 200 mg/ 5 mL Fco. x 90 mL 6.380 Gotas-Fco x 30 mL 2.724 200 mg Caja x 30 tabs. 6.100 Amp. x 1 g 7.287 Gotas-Fco x 15 mL 2.300 500 mg x 100 tabs. 12.401 ABILIFY BRISTOL Fco. x 60 mL 2.238 500 mg x 24 tabs. recub. 7.726 ACICLOVIR BCN MEDICAL Aripiprazol Fco. x 120 mL 4.030 Gotas x 30 ml 4.369 200 mg Caja x 25 tabs. 5.715 10 mg Caja x 10 tabs. 197.563 Jbe. x 90 ml 4.891 ACETAMINOFEN AMERICAN GENERICS ACICLOVIR BEST 15 mg Caja x 10 tabs. 194.644 ACETAMINOFEN OPHALAC Aciclovir 30 mg Caja x 10 tabs. 275.557 150 mg Jbe. x 60 mL 1.874 150 mg Jbe. x 90 mL 2.842 Acetaminofén 200 mg-Caja x 20 tabs. 3.725 ABRILAR SCANDINAVIA-ROEMMERS 500 mg Caja x 50 tabs. 4.540 Gotas Fco. x 30 mL 2.099 ACICLOVIR COASPHARMA S.A.S Efervescente Caja x 10 tabs. 21.383 500 mg Caja x 100 tabs. 6.090 Aciclovir ABRILAR SCANDINAVIA-ROEMMERS ACETAMINOFEN A-Z PHARMA 500 mg Caja x 24 tabs. 5.138 500 mg-Caja x 100 tabs. 4.300 200 mg plegadiza x 25 tabs. 56.871 Fco. 100 ml 21.709 Jbe. x 120 mL 3.748 200 mg/5ml susp. Fco. 90 mL 22.819 ABRILAR SCANDINAVIA-ROEMMERS ACETAMINOFEN BEST Jbe. x 60 mL 2.310 400 mg Caja x 30 tabs. 100.744 500 mg Caja x 20 tabs. 1.600 Jbe. Fco. x 200 ml 31.926 ACETAMINOFEN + CODEINA OPHALAC Ung. Tubo x 15 g 17.558 500 mg Caja x 250 tabs. 16.135 ABRILAR SCANDINAVIA-ROEMMERS Acetaminofén, Codeína 800 mg Plegadiza x 10 tabs. 80.403 Jbe. Fco. x 120 mL 3.345 x 15 Sachets x 5 ml 21.709 Caja x 30 tabs. 16.687 Jbe. Fco. x 60 mL 1.940 ACICLOVIR COLGENERICOS ABSORCAL-D PROANMED ACETATO ALUMINIO AMERICAN GENERICS Susp. Fco. x 90 mL 24.948 Calcio, Soya, Vitamina D ACETAMINOFEN BIOGENERICOS 200 mg Caja x 25 tabs. 65.543 100 mg/mL Gotas Fco. 30 mL 3.400 Aluminio, acetato de Fco. x 30 tabs. 15.500 Loción x 120 mL 3.500 Ung. al 5%-Tubo x 15 g 1.790 Fco. x 60 tabs. 24.800 Jbe. 150 mg/5 mL Fco. x 60 mL 3.300 Jbe. 150 mg/5 mL Fco. x 120 mL 5.500 Sobre x 25 11.022 ACICLOVIR COLMED ACAR KLEAN PROCAPS ACETATO ALUMINIO LAFRANCOL 200 mg Caja x 25 tabs. 12.210 Líq. Spray 400 cc 32.715 500 mg Caja x 100 tabs. 14.300 ACETAMINOFEN BIOQUIMICO PHARMA Locion x 120 ml 2.813 ACICLOVIR EXPOFARMA ACCUPRIL PFIZER Polvo 2.2 g x 25 sobres 7.125 Jbe. 3 g. Fco x 60 mL 1.275 Ung. Tubo x 15 g 3.570 10 mg Caja x 21 tabs. 80.127 800 mg-Caja x 10 tabs. 21.054 20 mg Caja x 21 tabs. 113.711 Jbe. 3 g. Fco x 120 mL 1.795 ACETATO DE ALUMINIO LICOL Aluminio, acetato de ACICLOVIR GENERICOS DE COL. 40 mg Caja x 21 tabs. 110.591 Gotas. Fco x 30 mL 1.360 ACEITES Loción Fco. x 500 mL 14.433 Aciclovir CERO Caja x 100. tabs. 5.066 Aceite con Vit E x 100 mL 3.250 Loción Fco. x 120 mL 3.960 250 mg Caja x 1 vial+amp. x 10 mL 15.000 Aceite con Vit E x 250 mL 6.300 ACETAMINOFEN COLGENERICOS Fco. x 500 mL 16.800 ACICLOVIR GENFAR Aceite con Vit E x 400 mL- 9.000 Acetaminofén ACETATO ALUMINIO OPHALAC 100 mg/5 mL PPS Fco. x 90 mL 5.546 Aceite con Vit E x 500 mL 9.800 Jbe. 3 g/100 mL-Fco. x 120 mL 2.089 Aluminio, acetato de 200 mg Caja x 25 tabs. 5.596 Aceite en gel x 160 mL colapsible 6.200 Jbe.3 g/100 mL-Fco. x 60 mL 2.519 Fco. x 120 mL 4.410 5% Ung. tópico Tubo x 15 g 4.355 ACEITE DE AGUACATE NATURAL FRESHLY 500 mg-Caja x 100 tabs. 6.945 Polvo x 25 sobres 10.500 800 mg Caja x 10 tabs. 8.820 Fco. x 240 ml 11.900 ACETAMINOFEN COASPHARMA S.A.S ACETATO DE ALUMINIO WINTHROP ACICLOVIR IFSA ACEITE DE AJONJOLI NATURAL FRESHLY Acetaminofén LOCIÓN WINTHROP - Aciclovir Fco. x 240 ml 11.900 100 mg/mL-Gotas Fco. x 30 mL 3.858 0.118 g/100 mL - pH 4.5 120 mL 3.333 200 mg Caja x 25 tabs. 5.405 ACEITE DE ALMENDRAS CIFAR 150 mg/5 mL Jbe. Fco. x 60 mL 2.888 ACETATO DE ALUMINIO WINTHROP ACICLOVIR LAFRANCOL Fco. x 25 mL 1.022 150 mg/5 mL-Jbe.-Fco x 90 mL 4.062 POLVO WINTHROP 200 mg x 30 tabs. 5.375 500 mg-Caja x 100 tabs. 12.295 Fco. x 450 mL 5.370 2,2 g - pH 4.2 25 sobres 6.908 ACICLOVIR LAPROFF ACETAMINOFEN DIZMOFAR ACEITE DE ALMENDRAS NATURAL FRESHLY ACETATO DE MEGESTR OL ALPHARMA Tabs. 200 mg Caja x 24 tabs. 2.670 Gotas Fco. x 30 mL 3.906 Fco. x 240 ml 11.900 160 mg tabs. 141.000 Tabs. 200 mg Caja x 240 tabs. (Multipack) 18.900 500 mg-Caja x 100 tabs. 12.320 ACEITE DE GERMEN DE TRIGO NATURAL ACETAZOLAMIDA BLASKOV ACICLOVIR LA SANTE ACETAMINOFEN GENERICOS DE COL. FRESHLY 250 mg Caja x 30 tabs. 57.200 4.693 500 mg-Caja x 100 tabs. 10.800 200 mg Caja x 24 tabs. Fco. x 240 ml 11.900 ACETICIN IFSA ACETAMINOFEN GENFAR ACICLOVIR LICOL ACEITE DE HIGADO DE BACALAO NATURAL Jbe. 3 g/100 mL- Fco. x 60 mL 1.740 5%-Ung. Tubo x 15 g 3.138 FRESHLY 150 mg/5 mL Jbe. Fco. x 60 mL 1.832 500 mg Caja x 100 tabs. 12.814 ACYCLOVIR MEMPHIS Fco. x 60 Softgels 15.000 500 mg Caja x 100 tabs. 7.378 Gotas 100 mg/mL-Fco. x 15 mL 1.558 ACEITE DE HIGADO DE BACALAO PROCAPS GOTAS 100 mg/mL Fco. x 30 mL 2.477 5%-Ung. Tubo x 15 g 15.800 150 mg Caja x 150 cáps. 35.714 ACETAMINOFEN GENOMA PHARMA ACETILCISTEÍNA ECAR 200 mg-Caja x 25 tabs. 41.000 150 mg Fco. x 50 cáps. 12.647 Jbe. 150 mg/5 mL Fco. x 60 mL 3.000 Polvo Caja x 30 sobres x 1,5 g 27.500 ACYCLOVIR MK A Polvo Reconstituir al 2% Fco. x 60 mL 8.700 ACEITE DE MANO DE RES NATURAL FRESHLY Jbe. 150 mg/5 mL Fco. x 90 mL 4.200 200 mg x 25 tabs. 6.299 Fco. x 240 ml 11.900 ACETAMINOFEN LABINCO ACETILCISTEÍNA WINTHROP WINTHROP 5% ung. tóp. x 10 g 3.576 ACEITE DE MANZANILLA CIFAR 100 mg/ mL Gotas Fco. x 15 mL 1.500 200 mg (sabor a naranja) 30 sobres 12.424 800 mg 7.823 Fco. x 25 mL 1.032 100 mg/ mL Gotas Fco. x 30 mL 1.800 ACETIL COLINA (OQ MIOT) OFTALMOQUIMICA ACICLOVIR OPHALAC ACEITE MINERAL CIFAR 150 mg/5 mL Jbe. Fco. x 60 mL 2.250 Fco. amp. Liofil. x 2 mL 26.964 800 mg Caja x 10 tabs. 6.300 x 25 mL 1.080 500 mg Caja x 100 tabs. 7.000 ACETIL COLINA INTRAOCULAR 1% QUIFARMED Polvo x 100 mL 8.938 x 450 mL 5.421 ACETAMINOFEN LAFRANCOL Liofilizado 26.000 200 mg-Caja x 25 tabs. 41.000 ACEITE DE NARANJA NATURAL FRESHLY 500 mg x 100 tabs. 5.125 ACEVITAL NX NEVOX FARMA 5%-Ung.
Load more

Recommended publications
  • First Quarter 2019
    Press release First quarter 2019 Issued: Wednesday, 1 May 2019, London U.K. GSK delivers sales of £7.7 billion +6% AER, +5% CER Total EPS 16.8p, +50% AER, +42% CER; Adjusted EPS 30.1p, +22% AER, +18% CER Financial highlights • Pharmaceuticals sales £4.2 billion, +4% AER, +2% CER; Vaccines £1.5 billion, +23% AER, +20% CER; Consumer Healthcare £2.0 billion, flat AER, +1% CER. • Total Group operating margin 18.6%. Adjusted Group operating margin 28.2%, +1.6 percentage points AER, +1.0 percentage point CER (Pharmaceuticals 29.8%; Vaccines 40.3%; Consumer Healthcare 21.7%). Benefits from strong sales growth and phasing of R&D. • Total EPS 16.8p, +50% AER, +42% CER. • Adjusted EPS 30.1p, +22% AER, +18% CER, driven by strong operating performance, continued financial efficiencies, reduction in minority share and a one-off benefit to associates. • Net cash flow from operations £663 million. Free cash flow £165 million. • 19p dividend declared for the quarter; continue to expect 80p for full year 2019. • 2019 Guidance reaffirmed. Product and pipeline highlights • Total HIV sales £1.1 billion, +7% AER, +4% CER, including Juluca sales of £70 million. - Dovato (dolutegravir+lamivudine), first once-daily 2-drug regimen for treatment-naive HIV patients, launched in US. - Long-acting cabotegravir+rilpivirine filed in the US for treatment of HIV. • Total new Respiratory product sales £631 million, +29% AER, +25% CER, including Trelegy £87 million; Nucala £152 million. • Shingrix sales £357 million driven by continued strong launch execution in US. • Continued
    [Show full text]
  • Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG
    EN Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 11/01/2001 Also available in the CELEX database Document No 301M2192 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 11.01.2001 SG(2000)D/285020 In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EEC) No 4064/89 concerning non-disclosure of business secrets and other confidential information. The omissions are MERGER PROCEDURE shown thus […]. Where possible the information ARTICLE 6(1)(b) DECISION omitted has been replaced by ranges of figures or a general description. To the notifying party Dear Sir/Madam, Subject: Case No COMP/M.2192 – SmithKline Beecham/Block Drug Notification of 17.11.2000 pursuant to Article 4 of Council Regulation No 4064/89 1. On 17 November, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (“the Merger Regulation”), by which the UK company, SmithKline Beecham plc (“SB”) notified its intention to acquire sole control over the US company, Block Drug Company Inc. (“Block Drug”), through purchase of shares. 2. Following examination of the notification, the Commission has concluded that the notified operation falls within the scope of the said Council Regulation and does not raise serious doubts as to its compatibility with the common market and the EEA agreement.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 2015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals, Vaccines and Consumer Healthcare businesses Overview of 2015 Strategic report “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business. This progress means the Group is well positioned to return to core earnings growth in 2016.” Sir Andrew Witty, Chief Executive Officer Governance & remunerationPerformance Financial statements summary Investor information £23.9bn £10.3bn £5.7bn £3.9bn Group turnover Total operating profit Core operating profit Cash dividends paid (up 6% CER/up 1% CER (up >100% CER) a (down 9% CER/down 3% in 2015 pro-forma) a CER pro-forma)a £2.0bn 174.3p 75.7p 10 0 % New product sales b Total earnings per share Core earnings per share Markets now operating (up >100%) (up >100%, primarily (down 15% CER, primarily new commercial model reflecting impact of reflecting short-term dilution transaction gains) of the Novartis transaction)a ~40 20 ~13 % 1st Potential new medicines Potential to file up to Estimated internal In Access to Medicine and vaccines profiled at R&D 20 assets with regulators rate of return in R&D Index event, 80% of which have by 2020 in 2015 potential to be first-in-classc Footnotes a We use a number of adjusted measures to report the performance of our business, as described on page 54. These include core results, CER growth rates and pro-forma CER growth rates. A reconciliation of total results to core results is set out on page 62.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 2015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals, Vaccines and Consumer Healthcare businesses Overview of 2015 Strategic report “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business. This progress means the Group is well positioned to return to core earnings growth in 2016.” Sir Andrew Witty, Chief Executive Officer Governance & remunerationPerformance Financial statements summary Investor information £23.9bn £10.3bn £5.7bn £3.9bn Group turnover Total operating profit Core operating profit Cash dividends paid (up 6% CER/up 1% CER (up >100% CER) a (down 9% CER/down 3% in 2015 pro-forma) a CER pro-forma)a £2.0bn 174.3p 75.7p 10 0 % New product sales b Total earnings per share Core earnings per share Markets now operating (up >100%) (up >100%, primarily (down 15% CER, primarily new commercial model reflecting impact of reflecting short-term dilution transaction gains) of the Novartis transaction)a ~40 20 ~13 % 1st Potential new medicines Potential to file up to Estimated internal In Access to Medicine and vaccines profiled at R&D 20 assets with regulators rate of return in R&D Index event, 80% of which have by 2020 in 2015 potential to be first-in-classc Footnotes a We use a number of adjusted measures to report the performance of our business, as described on page 54. These include core results, CER growth rates and pro-forma CER growth rates. A reconciliation of total results to core results is set out on page 62.
    [Show full text]
  • Annual Report 2017
    Annual Report Image HIV virus 2 017 GSK Annual Report 2017 GSK is a science-led global healthcare company In the Strategic report Our new CEO discusses Measuring performance 2017 performance and our and managing risk new long-term priorities See pages 05–07 See pages 18–21 How we create Innovation and Performance long-term value in each of our three businesses See pages 08–09 See pages 22–41 Industry trends How our three businesses together contribute to our Trust priority See pages 10–11 See pages 42–51 Our new long-term priorities: Financial review Innovation, Performance and Trust See pages 12–17 See pages 52–78 Cover image Cautionary statement 30 years after developing the first HIV See the inside back cover of this document medicine, our research into treatment and for the cautionary statement regarding prevention of HIV continues. We remain forward-looking statements. at the forefront of helping people living with HIV, driving innovation and working with communities all over the world. 01 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Our financial performance in 2017a £30.2bn AER +8% £6.7bn AER +51% Group turnover CER +3% New product salesb CER +44% £4.1bn AER +57% £8.6bn AER +12% Total operating profit CER +39% Adjusted operating profit CER +5% 31.4p AER +67% 111.8p AER +11% Total earnings per share CER +36% Adjusted earnings per share CER +4% £6.9bn £3.4bn £3.9bn 80p Net cash flow from Free cash flow Dividends declared 2017 dividend operating activities for 2017 per
    [Show full text]
  • GSK to Acquire Full Ownership of Consumer Healthcare Business
    Accelerating our strategy: GSK to acquire full ownership of Consumer Healthcare Business Buyout of Novartis’ stake Strategic review of Horlicks and other Consumer Healthcare Nutrition products Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.
    [Show full text]
  • راتفرannual Report 2019
    THE BLUE DOT GlaxoSmithKline Consumer Healthcare Pakistan Limited 35 - Dockyard Road, West Wharf, Karachi - 74000 GlaxoSmithKline Consumer Healthcare Pakistan Limited REPORT 2019 رفتارis a member of GlaxoSmithKline group of companies. ANNUAL © GlaxoSmithKline Consumer Healthcare Pakistan Limited GLAXOSMITHKLINE CONSUMER HEALTHCARE PAKISTAN LIMITED GSK Consumer Healthcare Pakistan Limited is proud to present its Annual Report for the year 2019. This report focuses on Stakeholder Information, Corporate Governance, Directors’ Report and Financial Statements for the year ended December 31, 2019. For any feedback, suggestions or queries kindly contact the following: Talal Javed Ahmed Chief Financial Ocer E-mail: [email protected] Abdul Haseeb Pirzada Head of Corporate Aairs and Administration Email: [email protected] رفتار STRONGER, FEARLESS, AGILE Amongst many our ‘Raftaar – speed’ stands out alone - GSK Consumer Healthcare Pakistan Limited's (GSK CH's) identity is accounted for being undoubtedly the best fast-moving consumer healthcare company in Pakistan. We set foot in this journey back in 2017 when GSK CH took its Flight (Uraan) with relentless motivation and unwavering energy. We moved forward in 2018 and created our Identity (Pehchaan) when we had committed to deliver only the best to our consumers. Keeping our core values at heart, we remained patient focused, transparent, respectful and most importantly carried our integrity above all. These elements led us to this day where we excelled in this corporate race with a new profound strength; accelerating with a speed (Raftaar) not just to be the best but to be the number one choice for our consumers in Pakistan. This strength for speed was not easy in such economic times with currency devaluation, regulatory frameworks and a competitive landscape.
    [Show full text]
  • Investor Information Information Investor Information
    Strategic report report Governance and and remuneration remuneration Financial statements statements Investor information information Investor information In this section Quarterly trend 244 Pharmaceuticals turnover 246 Vaccines turnover 248 Five year record 249 Product development pipeline 255 Products, competition and intellectual property 258 Principal risks and uncertainties 261 Share capital and control 276 Dividends 278 Financial calendar 2021 279 Annual General Meeting 2021 279 Tax information for shareholders 280 Shareholder services and contacts 282 US law and regulation 284 Group companies 287 Glossary of terms 299 GSK Annual Report 2020 243 Financial record Quarterly trend An unaudited analysis of the Group results is provided by quarter in Sterling for the financial year 2020. Income statement – Total 12 months 2020 Q4 2020 Q3 2020 Q2 2020 Q1 2020 Reported Pro-forma Reported Reported Reported Reported £m £% CER% CER% £m £% CER% £m £% CER% £m £% CER% £m £% CER% Turnover Pharmaceuticals 17,056 (3) (1) (1) 4,366 (4) (3) 4,192 (7) (3) 4,102 (5) (5) 4,396 6 6 Vaccines 6,982 (2) (1) (1) 2,012 15 16 2,032 (12) (9) 1,133 (29) (29) 1,805 19 19 Consumer Healthcare 10,033 12 14 (2) 2,360 (8) (7) 2,422 (4) 2 2,389 25 25 2,862 44 46 34,071 1 3 (2) 8,738 (1) – 8,646 (8) (3) 7,624 (2) (3) 9,063 18 19 Corporate and other unallocated turnover 28 1 – – 27 Total turnover 34,099 1 3 (2) 8,739 (2) (1) 8,646 (8) (3) 7,624 (2) (3) 9,090 19 19 Cost of sales (11,704) (1) – (3,171) (2) (2) (2,885) (11) (8) (2,449) (7) (7) (3,199) 17 18 Selling, general
    [Show full text]
  • Annual Report 2016
    Annual Report 2016 2016 saw good sales momentum across Pharmaceuticals, Vaccines and Consumer Healthcare and further pipeline progress We are a global science-led healthcare company. Our three world-leading businesses research and deliver innovative medicines, vaccines and consumer healthcare products. Front cover case study At GSK, innovation underpins each of our three businesses We are using next generation technology return on R&D investment and accelerate to develop new approaches to disease the development of new products that can management and control. In addition to improve patients’ lives. our own research and development, We have an active pipeline of innovative we gain insights through our network of products across six core areas: respiratory, collaborations with biotechs, other HIV and infectious diseases, vaccines, companies and academic institutions. immuno-inflammation, oncology and This enables more efficient trial design rare diseases. and greater use of software, analytics and new technology, all of which is helping to increase our productivity, maximise our Arthur works at our Upper Providence R&D lab Cautionary statement regarding forward-looking statements The Group’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document and written information released, or oral statements made, to the public in the future by or on behalf of the Group, may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance.
    [Show full text]
  • Alphabetical Listing by Name Dod UNIFORM OUTPATIENT
    DoD UNIFORM OUTPATIENTFORMULARY Alphabetical Listing by Name This document is current as of July 14, 2021 The availability of formulary items is subject to change. Basic Core Formulary: MTF must have on formulary Uniform Formulary: MTF may have on formulary Nonformulary: MTF must not have on formulary Extended Core Formulary: MTF must be on formulary if includes any drugs from that drug class 1 ABACAVIR Abacavir Capsule, Oral: DoD Uniform Formulary Outpatient Dosage Forms Mapap Extra Strength: 500 mg UNIFORM FORMULARY Elixir, Oral: Solution, Oral: Mapap Children's: 160 mg/5 mL (118 mL, 480 mL) [ethanol free; contains Ziagen: 20 mg/mL (240 mL) [contains methylparaben, propylene glycol, benzoic acid, propylene glycol, sodium benzoate; cherry flavor] propylparaben, saccharin sodium; strawberry-banana flavor] Injection, Solution [preservative free]: Tablet, Oral: Ofirmev: 10 mg/mL (100 mL) Generic: 300 mg Liquid, Oral: Generic: 160 mg/5 mL (120 mL, 473 mL); 500 mg/5 mL (240 mL) Abacavir and Lamivudine Solution, Oral: DoD Uniform Formulary Outpatient Dosage Forms Generic: 160 mg/5 mL (5 mL, 10 mL, 20 mL) UNIFORM FORMULARY Suppository, Rectal: Tablet, Oral: Generic: 120 mg (12s); 325 mg (12s) Generic: Abacavir 600 mg and lamivudine 300 mg Suspension, Oral: Generic: 160 mg/5 mL (5 mL, 10.15 mL, 20.3 mL) Abacavir, Dolutegravir, and Lamivudine Syrup, Oral: DoD Uniform Formulary Outpatient Dosage Forms Triaminic Children's Fever Reducer Pain Reliever: 160 mg/5 mL (118 mL) UNIFORM FORMULARY Tablet, Oral: Tablet, Oral: Generic: 325 mg, 500 mg Triumeq:
    [Show full text]
  • Your 2020 Over-The-Counter Ordering Catalog
    Your 2020 Over-the-Counter Ordering Catalog Hundreds of common health products you can buy with your Gateway Health benefit. Look Inside for More Details and How to Order. Use this Catalog Jan. 1, 2020-Dec. 31, 2020 Y0097_1537_M VISIT US ONLINE AT WWW.FIELDTEX-GATEWAY.COMY0097_1537_M1 2020_Gateway_OTC_Catalog.indd 1 9/26/19 10:01 AM Welcome! Start using your Over-the-Counter (OTC) benefit. Your Gateway Health coverage just keeps getting better. Starting January 1, 2020 you have access to hundreds of retail wellness products when you use your quarterly over-the-counter allowance. And even better, any unused portion of your quarterly allowance can be rolled over to the next quarter. It’s a service powered by our partners at Fieldtex, and it’s unbelievably simple to use. How Much You Get: $300 per Quarter $120 per Quarter Medicare Assured Medicare Assured DiamondSM Members RubySM Members Use this catalog to choose and order your health products from January 1, 2020 to December 31, 2020. All orders must be placed by then. See next page for easy instructions on how to order. 2 CALL US TOLL-FREE AT 1-855-350-0074 (TTY 711) Y0097_1537_M 2020_Gateway_OTC_Catalog.indd 2 9/26/19 10:01 AM Gateway Health Ordering Process 3 Easy Ways to Order Order Online Order by Phone www.Fieldtex-Gateway.com 1-855-350-0074 (TTY 711) Monday-Friday 8:00 AM to 5:00 PM Order by Mail Saturday 9:00 AM to 5:00 PM Fill out the attached mail order form and send it in the postage- Sunday paid envelope.
    [Show full text]
  • Press Release First Quarter 2018
    Press release First quarter 2018 Issued: Wednesday, 25 April 2018, London U.K. GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER Total EPS 11.2p, -48% AER, -33% CER; Adjusted EPS 24.6p, -2% AER, +11% CER Significant currency impact in the quarter reflecting movements in Sterling F inancial highlights • CER sales growth across all 3 businesses. Pharmaceuticals sales £4.0 billion -4% AER, +2% CER; Vaccines £1.2 billion +7% AER, +13% CER; Consumer Healthcare £2.0 billion -3% AER, +2% CER • Adjusted Group operating margin of 26.6%, down 0.2 percentage points AER, up 1.3 percentage points CER. Pharmaceuticals 33.2%; Vaccines 27.4%; Consumer Healthcare 19.4% • Total EPS 11.2p, -48% AER, -33% CER, reflecting revaluation of Consumer Healthcare business following agreement to acquire full ownership • Adjusted EPS 24.6p, -2% AER, +11% CER driven by continued operating and financial efficiencies • Q1 free cash flow £324 million -50% primarily reflecting impact of £317 million Vaccine sales milestone payment to Novartis • 19p dividend declared for quarter. Continue to expect 80p for FY 2018 • Guidance for CER growth in Adjusted EPS for 2018 maintained Novartis transaction • Agreement reached with Novartis to acquire full ownership of Consumer Healthcare business for $13 billion, subject to shareholder approval P roduct and pipeline highlights • Sales of Ellipta Respiratory products, £386 million +25% AER, +34% CER and Nucala £104 million +76% AER, +86% CER. Landmark IMPACT data for Trelegy Ellipta published in NEJM. sNDA approved in US and data submitted to European Medicines Agency to support expanded label.
    [Show full text]